ClinicalTrials.gg
Status unknownNCT03662958Updated Sep 10, 2018

Comparison of a Novel Leuprolide With Market Leuprolide

An interventional study of Lutrate and Enantone in Prostate Cancer, sponsored by Lee's Pharmaceutical Limited. Status unknown at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Lee's Pharmaceutical Limited · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Planned enrollment
47th of 69
48 · median 77
Started
2018
with 1 other
No phase
5 of 70
1 open now
Registered
48th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 47th largest by planned enrollment of the 69 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 with no phase, and was the 48th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a single dose, randomized, single blind, parallel group study to evaluate the testosterone suppressive effect in healthy male volunteers of a novel leuprolide acetate 3.75mg depot vs market reference leuprolide acetate 3.75mg depot. The safety, tolerability and the pharmacokinetic properties of the investigational drug and the control drug will also be assessed.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males of 18-40 years old (inclusive). The age difference of subjects within and between groups should be less than 10 years, at the time of screening.
  2. Body weight of at least 50kg. to be 19-24 kg/m2 (inclusive).
  3. Able to comprehend the full nature and purpose of the study, including potential risks and side effects; able to cooperate with investigators and to comply with the requirements of the study
  4. Signed form prior to any screening procedures

Exclusion criteria

Exclusion Criteria:

  1. and relevant history of cardiovascular, hepatic, renal, hematologic, endocrine, respiratory, neurological diseases or acute/chronic diseases of the digestive tract.
  2. History of towards leuprolide, synthetic LHRH or LHRH derivatives or any of the study formulation.
  3. Abnormal and clinically significant 12-lead
  4. Abnormal and clinically significant laboratory assessments
  5. Blood donation or blood loss greater than or equal to 400mL within 3 months prior to screening
  6. Participation of clinical trials within 3 months prior to screening
  7. Use of any drugs within 2 weeks prior to screening
  8. History of drug abuse within 1 year prior to screening
  9. History of alcohol abuse within 1 years prior to screening
  10. History of tobacco smoking (more than 5 cigarette per day) within 1 year prior to screening
  11. Abnormal testosterone level at screening (not in the range of 168-781ng/dL)
  12. Dermatitis or skin anomalies that might affect the administration area and the surroundings
  13. Subject or his partner not willing to adopt appropriate measures
  14. Subjects have a history of depressive illness or sexual dysfunction;
  15. Subjects that the investigator deems unsuitable to be enrolled
  16. Subject not willing to cooperate with the investigators.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Lutrate

    a novel leuprolide acetate 3.75mg depot

    Drug: Lutrate

  • Active comparator
    Enantone

    market reference leuprolide acetate 3.75 mg depot

    Drug: Enantone

Interventions

  • a novel leuprolide acetate 3.75mg depot

  • market reference leuprolide acetate 3.75 mg depot

06

What researchers measure

Primary outcomes

  1. The rate of castration at the end of week 4 (i.e. day 29)

    Time frame: 4 weeks

Secondary outcomes

  1. The time to castration (i.e Tlag) between the 2 groups after administration of leuprolide

    Time frame: 4 weeks

  2. The duration of castration (i.e Tcast)

    Time frame: 4 weeks

  3. LH concentration

    Time frame: 4 weeks

  4. FSH concentration

    Time frame: 4 weeks

Other outcomes

  1. Adverse events

    Time frame: 4 weeks

  2. Local tolerability

    (10) Subjects will evaluate pain with VAS. Investigators will evaluate redness and induration with a 4-point scale.

    Time frame: post-dose 5 min and 1 hour, day 8, 15 and 29

  3. AE

    Time frame: 4 weeks

  4. blood pressure

    Time frame: 4 weeks

  5. pulse rate

    Time frame: 4 weeks

  6. respiratory rate

    Time frame: 4 weeks

  7. body temperature

    Time frame: 4 weeks

  8. 12-lead ECG

    Time frame: 4 weeks

  9. body weight

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Oct 2018, 2 months after the start.

Of 57 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 2 months is below that.

Counting every sponsor, half of 1,155 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Sep 10, 2018
StartActual
Aug 1, 2018
Primary completionEst.
Oct 2018
CompletionEst.
Dec 2018
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03662958
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Aug 1, 2018
Primary completion
Oct 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Sep 10, 2018

Study contacts

Hongju Wang, MD
Contact
wanghongju@bbmu.edu.cn
0552-3086026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion